Truist Lowers Price Target on Inari Medical to $46 From $55, Keeps Hold Rating
Inari Medical Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Day One Biopharmaceuticals (DAWN) and Inari Medical (NARI)
Bank of America Securities Remains a Buy on Inari Medical (NARI)
Inari Medical Analyst Ratings
Stifel Initiates Coverage On Inari Medical With Hold Rating, Announces Price Target of $50
Stifel Initiates Inari Medical(NARI.US) With Hold Rating, Announces Target Price $50
Piper Sandler Maintains Inari Medical(NARI.US) With Hold Rating, Maintains Target Price $50
Piper Sandler Keeps Their Hold Rating on Inari Medical (NARI)
Deutsche Bank Maintains Inari Medical(NARI.US) With Buy Rating, Maintains Target Price $68
Inari Medical Price Target Maintained With a $50.00/Share by Piper Sandler
Inari Medical Analyst Ratings
Piper Sandler Maintains Neutral on Inari Medical, Maintains $50 Price Target
Inari Medical's Resilience and Market Potential Affirm Buy Rating
Analysts Offer Insights on Healthcare Companies: Inari Medical (NARI) and PROCEPT BioRobotics (PRCT)
Inari Medical Analyst Ratings
Inari Medical (NARI) Receives a New Rating From Deutsche Bank
CCORF Maintains Inari Medical(NARI.US) With Buy Rating, Maintains Target Price $71
Baird Maintains Inari Medical(NARI.US) With Buy Rating, Cuts Target Price to $63
Morgan Stanley Maintains Inari Medical(NARI.US) With Buy Rating, Maintains Target Price $60